Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer

Nat Commun. 2023 May 30;14(1):3130. doi: 10.1038/s41467-023-38750-9.


Clinical management of breast cancer (BC) metastasis remains an unmet need as it accounts for 90% of BC-associated mortality. Although the luminal subtype, which represents >70% of BC cases, is generally associated with a favorable outcome, it is susceptible to metastatic relapse as late as 15 years after treatment discontinuation. Seeking therapeutic approaches as well as screening tools to properly identify those patients with a higher risk of recurrence is therefore essential. Here, we report that the lipid-degrading enzyme fatty acid amide hydrolase (FAAH) is a predictor of long-term survival in patients with luminal BC, and that it blocks tumor progression and lung metastasis in cell and mouse models of BC. Together, our findings highlight the potential of FAAH as a biomarker with prognostic value in luminal BC and as a therapeutic target in metastatic disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amidohydrolases* / genetics
  • Animals
  • Biomarkers, Tumor*
  • Lung Neoplasms* / pathology
  • Mice
  • Neoplasm Recurrence, Local / pathology


  • Amidohydrolases
  • Biomarkers, Tumor
  • fatty-acid amide hydrolase